查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1307823

减脂的全球市场:产业趋势·预测 (～2030年)

Global Fat Reduction Market - Industry Trends and Forecast to 2030
出版日期: | 出版商: Data Bridge Market Research | 英文 2169 Pages | 商品交期: 请询问到货日

价格

全球减脂的市场规模将从2022年的107亿4,845万美元，在预测期间中将以9.5％的年复合成长率推移，2033年288亿1,702万美元的规模。

本报告提供全球减脂的市场调查，彙整市场概要，市场成长的各种影响因素分析，相关法律，类型·用途·性别·年龄层·终端用户·流通管道·地区/各主要国家的产业趋势·预测，主要企业简介等资讯。

目录

第1章 简介

第2章 市场分类

第3章 摘要整理

第4章 重要考察

  • PESTEL分析
  • 波特的五力分析
  • 市场分析
  • 北美 (费用·治疗的分析)
  • 欧洲 (费用·治疗的分析)
  • 亚太地区 (费用·治疗的分析)
  • 中东·非洲 (费用·治疗的分析)
  • 南美 (费用·治疗的分析)
  • 品牌分析
  • 价格分析
  • 全球减脂市场专利分析
  • 价格分析

第5章 产业考察

  • 人口动态趋势
  • 总论

第6章 全球减脂市场:法律规章

  • 美国
  • 加拿大
  • 墨西哥
  • 多明尼加共和国
  • 瓜地马拉

The global fat reduction market is expected to reach USD 28,817.02 million by 2033 from USD 10,748.45 million in 2022, growing at a CAGR of 9.5% during the forecast period of 2023 to 2033.

Market Segmentation:

Global Fat Reduction Market, By Type (Surgical Fat Reduction, Non-Invasive Fat Reduction, and Minimally Invasive), Application (Abdominal Fat, Thighs Fat, Buttock Fat, Upper-Arm Fat, Facial Fat, and Knee Fat), Gender (Female, Male), Age Group (Adult, Geriatric, and Child), End-User (Hospitals, Multi-Specialty Clinics, Dermatology Centers, Medical Spas, and Beauty Centers), Distribution Channel (Direct Tender, Retail Sales, Third Party Distributors and Others), Country (U.S.,Canada, Mexico, Costa Rica, Dominican Republic, Panama, El Salvador, Guatemala, Honduras, Nicaragua, Germany, Turkey, Italy, Poland, Spain, Russia, France, Netherlands, Switzerland, Belgium, Austria, Norway, Ireland, Hungary, Lithuania, Azerbaijan, U.K., Georgia, Ukraine, Rest of Europe, Japan India, China, South Korea, Thailand, Malaysia, Singapore, Australia, Philippines, Taiwan, Indonesia, New Zealand, Vietnam, Pakistan, Uzbekistan, Myanmar, Nepal, Cambodia, Rest of Asia-Pacific, Brazil, Argentina , Colombia, Chile, Peru, Ecuador, Bolivia, Paraguay, Rest of South America, Saudi Arabia, Egypt,UAE,South Africa, Israel, Kuwait, Qatar, Oman, Bahrain, Lebanon, Algeria, Jordan, Morocco, Iran, Libya, Iraq, Tunisia, Rest of Middle East and Africa) - Industry Trends and Forecast to 2033.

Overview of Global Fat Reduction Market Dynamics:

  • Driver
  • Increasing demand for minimally invasive and non-invasive procedures
  • Restrain
  • High cost of procedures
  • Opportunity
  • Customized treatment plans and integration with other aesthetic procedures

Market Players:

The key market players operating in the global fat reduction market are listed below:

  • AbbVie Inc.
  • Cynosure
  • Alma Lasers
  • Candela Corporation
  • Merz Pharma
  • Solta Medical (Subsidiary of Bausch & Lomb Incorporated)
  • Cutera
  • MicroAire Surgical Instruments, LLC.
  • Others

TABLE OF CONTENTS

1 INTRODUCTION 227

  • 1.1 OBJECTIVES OF THE STUDY 227
  • 1.2 MARKET DEFINITION 227
  • 1.3 OVERVIEW OF THE GLOBAL FAT REDUCTION MARKET 227
  • 1.4 CURRENCY AND PRICING 229
  • 1.5 LIMITATIONS 229
  • 1.6 MARKETS COVERED 230

2 MARKET SEGMENTATION 235

  • 2.1 MARKETS COVERED 235
  • 2.2 GEOGRAPHICAL SCOPE 236
  • 2.3 YEARS CONSIDERED FOR THE STUDY 237
  • 2.4 DBMR TRIPOD DATA VALIDATION MODEL 238
  • 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 241
  • 2.6 MULTIVARIATE MODELLING 242
  • 2.7 TYPE LIFELINE CURVE 242
  • 2.8 DBMR MARKET POSITION GRID 243
  • 2.9 VENDOR SHARE ANALYSIS 244
  • 2.10 MARKET APPLICATION COVERAGE GRID 245
  • 2.11 SECONDARY SOURCES 246
  • 2.12 ASSUMPTIONS 246

3 EXECUTIVE SUMMARY 247

4 PREMIUM INSIGHT 251

  • 4.1 PESTEL ANALYSIS 253
  • 4.2 PORTER'S FIVE FORCES 254
  • 4.3 MARKET ANALYSIS 255
  • 4.4 NORTH AMERICA (PRICING AND PROCEDURE ANALYSIS) 256
    • 4.4.1 U.S. 256
    • 4.4.2 CANADA 257
    • 4.4.3 MEXICO 258
    • 4.4.4 COSTA RICA 259
    • 4.4.5 DOMINICIAN REPUBLIC 260
    • 4.4.6 PANAMA 261
    • 4.4.7 EL SALVADOR 262
    • 4.4.8 GAUTEMALA 263
    • 4.4.9 HONDURAS 264
    • 4.4.10 NICARAGUA 265
  • 4.5 EUROPE (PRICING AND PROCEDURE ANALYSIS) 266
    • 4.5.1 GERMANY 266
    • 4.5.2 TURKEY 267
    • 4.5.3 ITALY 268
    • 4.5.4 POLAND 269
    • 4.5.5 SPAIN 270
    • 4.5.6 RUSSIA 271
    • 4.5.7 FRANCE 272
    • 4.5.8 NETHERLANDS 273
    • 4.5.9 SWITZERLAND 274
    • 4.5.10 BELIGUM 275
    • 4.5.11 AUSTRIA 276
    • 4.5.12 NORWAY 277
    • 4.5.13 IRELAND 278
    • 4.5.14 HUNGARY 279
    • 4.5.15 LITHUAMIA 280
    • 4.5.16 AZERBAIJAN 281
    • 4.5.17 U.K. 282
    • 4.5.18 GEORGIA 283
    • 4.5.19 UKRAINE 284
  • 4.6 ASIA PACIFIC (PRICING AND PROCEDURE ANALYSIS) 285
    • 4.6.1 JAPAN 285
    • 4.6.2 INDIA 286
    • 4.6.3 CHINA 287
    • 4.6.4 SOUTH KOREA 288
    • 4.6.5 THAILAND 289
    • 4.6.6 MALAYSIA 290
    • 4.6.7 SINGAPORE 291
    • 4.6.8 AUSTRALIA 292
    • 4.6.9 PHILIPPINES 293
    • 4.6.10 TAIWAN 294
    • 4.6.11 INDONESIA 295
    • 4.6.12 NEW ZEALAND 296
    • 4.6.13 VIETNAM 297
    • 4.6.14 PAKISTAN 298
    • 4.6.15 UZBEKISTAN 299
    • 4.6.16 MYANMAR 300
    • 4.6.17 NEPAL 301
    • 4.6.18 COMBODIA 302
  • 4.7 MIDDLE EAST & AFRICA (PRICING AND PROCEDURE ANALYSIS) 303
    • 4.7.1 SAUDI ARABIA 303
    • 4.7.2 EGYPT 304
    • 4.7.3 UAE 305
    • 4.7.4 SOUTH AFRICA 306
    • 4.7.5 ISRAEL 307
    • 4.7.6 KUWAIT 308
    • 4.7.7 QATAR 309
    • 4.7.8 OMAN 310
    • 4.7.9 BAHRAIN 311
    • 4.7.10 LEBANON 312
    • 4.7.11 ALGERIA 313
    • 4.7.12 JORDAN 314
    • 4.7.13 MOROCCO 315
    • 4.7.14 IRAN 316
    • 4.7.15 LIBIYA 317
    • 4.7.16 IRAQ 318
    • 4.7.17 TUNISIA 319
  • 4.8 SOUTH AMERICA (PRICING AND PROCEDURE ANALYSIS) 320
    • 4.8.1 BRAZIL 320
    • 4.8.2 ARGENTINA 321
    • 4.8.3 COLOMBIA 322
    • 4.8.4 CHILE 323
    • 4.8.5 PERU 324
    • 4.8.6 EQUADOR 325
    • 4.8.7 BOLIVIA 326
    • 4.8.8 PARAGUAY 327
  • 4.9 BRAND ANALYSIS 328
    • 4.9.1 KYBELLA 328
    • 4.9.2 AQUALYX 329
  • 4.10 PRICING ANALYSIS (USD) 330
    • 4.10.1 NORTH AMERICA 330
      • 4.10.1.1 U.S. 330
      • 4.10.1.2 CANADA 330
      • 4.10.1.3 MEXICO 330
      • 4.10.1.4 COSTA RICA 331
      • 4.10.1.5 DOMINICIAN REPUBLIC 331
      • 4.10.1.6 PANAMA 331
      • 4.10.1.7 EL SALVADOR 332
      • 4.10.1.8 GAUTEMALA 332
      • 4.10.1.9 HONDURAS 332
      • 4.10.1.10 NICARAGUA 333
    • 4.10.2 EUROPE 334
      • 4.10.2.1 GERMANY 334
      • 4.10.2.2 TURKEY 334
      • 4.10.2.3 ITALY 334
      • 4.10.2.4 POLAND 335
      • 4.10.2.5 SPAIN 335
      • 4.10.2.6 RUSSIA 335
      • 4.10.2.7 FRANCE 336
      • 4.10.2.8 NETHERLANDS 336
      • 4.10.2.9 SWITZERLAND 336
      • 4.10.2.10 BELIGUM 337
      • 4.10.2.11 AUSTRIA 337
      • 4.10.2.12 NORWAY 337
      • 4.10.2.13 IRELAND 338
      • 4.10.2.14 HUNGARY 338
      • 4.10.2.15 LITHUAMIA 338
      • 4.10.2.16 AZERBAIJAN 339
      • 4.10.2.17 U.K. 339
      • 4.10.2.18 GEORGIA 339
      • 4.10.2.19 UKRAINE 340
    • 4.10.3 ASIA-PACIFIC 341
      • 4.10.3.1 JAPAN 341
      • 4.10.3.2 INDIA 341
      • 4.10.3.3 CHINA 341
      • 4.10.3.4 SOUTH KOREA 342
      • 4.10.3.5 THAILAND 342
      • 4.10.3.6 MALAYSIA 342
      • 4.10.3.7 SINGAPORE 343
      • 4.10.3.8 AUSTRALIA 343
      • 4.10.3.9 PHILIPPINES 343
      • 4.10.3.10 TAIWAN 344
      • 4.10.3.11 INDONESIA 344
      • 4.10.3.12 NEW ZEALAND 344
      • 4.10.3.13 VIETNAM 345
      • 4.10.3.14 PAKISTAN 345
      • 4.10.3.15 UZBEKISTAN 345
      • 4.10.3.16 MYANMAR 346
      • 4.10.3.17 NEPAL 346
      • 4.10.3.18 COMBODIA 346
    • 4.10.4 SOUTH AMERICA 347
      • 4.10.4.1 BRAZIL 347
      • 4.10.4.2 ARGENTINA 347
      • 4.10.4.3 COLOMBIA 347
      • 4.10.4.4 CHILE 348
      • 4.10.4.5 PERU 348
      • 4.10.4.6 EQUADOR 348
      • 4.10.4.7 BOLIVIA 349
      • 4.10.4.8 PARAGUAY 349
    • 4.10.5 MIDDLE EAST & AFRICA 350
      • 4.10.5.1 SAUDI ARABIA 350
      • 4.10.5.2 EGYPT 350
      • 4.10.5.3 UAE 350
      • 4.10.5.4 SOUTH AFRICA 351
      • 4.10.5.5 ISRAEL 351
      • 4.10.5.6 KUWAIT 351
      • 4.10.5.7 QATAR 352
      • 4.10.5.8 OMAN 352
      • 4.10.5.9 BAHRAIN 352
      • 4.10.5.10 LEBANON 352
      • 4.10.5.11 ALGERIA 353
      • 4.10.5.12 JORDAN 353
      • 4.10.5.13 MOROCCO 353
      • 4.10.5.14 IRAN 353
      • 4.10.5.15 LIBIYA 354
      • 4.10.5.16 IRAQ 354
      • 4.10.5.17 TUNISIA 354
  • 4.11 PATENT ANALYSIS OF THE GLOBAL FAT REDUCTION MARKET 355
    • 4.11.1 U.S. 355
      • 4.11.1.1 METHODS FOR THE PURIFICATION OF DEOXYCHOLIC ACID 355
      • 4.11.1.2 COMPOSITIONS COMPRISING DEOXYCHOLIC ACID AND SALTS THEREOF SUITABLE FOR USE IN TREATING EAT DEPOSITS 356
      • 4.11.1.3 FORMULATIONS OF DEOXYCHOLIC ACID AND SALTS THEREOF 357
      • 4.11.1.4 SYNTHETIC BILE ACID COMPOSITIONS AND METHODS 357
    • 4.11.2 CANADA 358
      • 4.11.2.1 SYNTHETIC BILE ACID COMPOSITIONS AND METHODS 358
      • 4.11.2.2 BELKYRA 358
      • 4.11.2.3 BELKYRA 359
      • 4.11.2.4 BELKYRA 359
    • 4.11.3 MEXICO 360
      • 4.11.3.1 FORMULATIONS OF DEOXYCHOLIC ACID AND SALTS THEREOF. 360
      • 4.11.3.2 TREATMENTS OF ACCUMULATED FAT WITH DEOXYCHOLIC ACID AND SALTS THEREOF. 360
    • 4.11.4 EUROPE 361
      • 4.11.4.1 FORMULATIONS OF DEOXYCHOLIC ACID AND SALTS THEREOF 361
      • 4.11.4.2 SYNTHESIS OF DEOXYCHOLIC ACID (DCA) 362
      • 4.11.4.3 METHOD AND COMPOSITION FOR REDUCING SUBCUTANEOUS FAT 363
      • 4.11.4.4 METHOD AND COMPOSITION FOR REDUCING SUBCUTANEOUS FAT DEPOSITS 364
    • 4.11.5 HUNGARY 365
      • 4.11.5.1 FORMULATIONS OF DEOXYCHOLIC ACID AND SALTS THEREOF 365
    • 4.11.6 JAPAN 365
      • 4.11.6.1 FORMULATION OF DEOXYCHOLIC ACID AND ITS SALTS 365
      • 4.11.6.2 METHOD FOR TREATING ACCUMULATED FAT WITH DEOXYCHOLIC ACID AND ITS SALTS 366
      • 4.11.6.3 FORMULATION OF DEOXYCHOLIC ACID AND ITS SALTS 366
      • 4.11.6.4 FORMULATION OF DEOXYCHOLIC ACID AND ITS SALTS 367
    • 4.11.7 AUSTRALIA 367
      • 4.11.7.1 TREATMENTS OF ACCUMULATED FAT WITH DEOXYCHOLIC ACID AND SALTS THEREOF 367
      • 4.11.7.2 FORMULATIONS OF DEOXYCHOLIC ACID AND SALTS THEREOF 368
    • 4.11.8 CHINA 369
      • 4.11.8.1 THE PREPARATION OF DEOXYCHOLIC ACID AND ITS SALT 369
      • 4.11.8.2 FORMULATIONS OF DEOXYCHOLIC ACID AND SALTS THEREOF 369
      • 4.11.8.3 TREATMENT USING DEOXYCHOLIC ACID AND ITS SALT TO THE FAT OF ACCUMULATION 370
    • 4.11.9 SOUTH AFRICA 371
      • 4.11.9.1 FORMULATIONS OF DEOXYCHOLIC ACID AND SALTS THEREOF 371
    • 4.11.10 INDIA 371
    • 4.11.11 SOUTH KOREA 371
  • 4.12 PRICING ANALYSIS (USD) 373
    • 4.12.1 KYBELLA 373
    • 4.12.2 COOLSCULPTING 375
    • 4.12.3 COOLSCULPTING ELITE 377
    • 4.12.4 COOLTONE 379

5 INDUSTRY INSIGHTS: 382

  • 5.1 DEMOGRAPHIC TRENDS: 383
  • 5.2 CONCLUSION: 384

6 GLOBAL FAT REDUCTION MARKET, REGULATIONS 385

  • 6.1 U.S. 385
    • 6.1.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE: 385
    • 6.1.2 POST-MARKETING SURVEILLANCE: 387
    • 6.1.3 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES: 387
  • 6.2 CANADA 388
    • 6.2.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 388
    • 6.2.2 LICENSING AND REGISTRATION 389
    • 6.2.3 POST EXPIRY OF PATENT REGIME 389
    • 6.2.4 POST-MARKETING SURVEILLANCE 389
  • 6.3 MEXICO 390
    • 6.3.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 390
    • 6.3.2 REGULATORY APPROVAL AGENCIES 390
    • 6.3.3 LICENSING AND REGISTRATION 391
    • 6.3.4 POST-MARKETING SURVEILLANCE 391
  • 6.4 DOMINICAN REPUBLIC 391
    • 6.4.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 391
    • 6.4.2 RENEWAL OF REGISTRATION IS REQUIRED IF THERE IS A CHANGE IN PRODUCT FORMULATION OR A CHANGE IN THE SITE OF MANUFACTURE. 392
    • 6.4.3 TIMELINE 393
  • 6.5 GUATEMALA 393
    • 6.5.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 393
    • 6.5.2 REGULATORY APPROVAL AGENCIES 393
    • 6.5.3 LICENSING AND REGISTRATION 394
    • 6.5.4 POST-MARKETING SURVEILLANCE 394
    • 6.5.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 394
  • 6.6 HONDURAS 394
    • 6.6.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 394
    • 6.6.2 REGULATORY APPROVAL AGENCIES 394
  • 6.7 NICARAGUA 395
    • 6.7.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 395
    • 6.7.2 LICENSING AND REGISTRATION 395
    • 6.7.3 POST-MARKETING SURVEILLANCE 395
  • 6.8 GERMANY 395
    • 6.8.1 REGULATORY APPROVAL AGENCIES AND PROCESS 395
  • 6.9 FRANCE 396
    • 6.9.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 396
    • 6.9.2 REGULATORY APPROVAL AGENCIES 396
    • 6.9.3 POST-MARKETING SURVEILLANCE 396
  • 6.10 U.K. 396
    • 6.10.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 396
    • 6.10.2 GENERIC MARKET 397
    • 6.10.3 REGULATORY APPROVAL AGENCIES 397
    • 6.10.4 LICENSING AND REGISTRATION 398
    • 6.10.5 POST-MARKETING SURVEILLANCE 399
  • 6.11 ITALY 399
    • 6.11.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 399
    • 6.11.2 REGULATORY APPROVAL AGENCIES 399
    • 6.11.3 LICENSING AND REGISTRATION 400
    • 6.11.4 POST-MARKETING SURVEILLANCE 400
    • 6.11.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 400
  • 6.12 SPAIN 400
    • 6.12.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 400
    • 6.12.2 REGULATORY APPROVAL AGENCIES 400
    • 6.12.3 LICENSING AND REGISTRATION 400
  • 6.13 RUSSIA 401
    • 6.13.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 401
    • 6.13.2 TIMELINE 401
    • 6.13.3 REGULATORY APPROVAL AGENCIES 401
    • 6.13.4 LICENSING AND REGISTRATION 401
    • 6.13.5 GOOD MANUFACTURING PRACTICES 402
    • 6.13.6 TIMELINES FOR RUSSIAN GMP CERTIFICATE 402
  • 6.14 TURKEY 403
    • 6.14.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 403
    • 6.14.2 REGULATORY APPROVAL AGENCIES 403
    • 6.14.3 LICENSING AND REGISTRATION 403
    • 6.14.4 POST-MARKETING SURVEILLANCE 404
    • 6.14.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 404
  • 6.15 AZERBAIJAN 404
    • 6.15.1 THE FOLLOWING TERMS ARE USED IN THE PRESENT REGULATIONS: 404
    • 6.15.2 PROCEDURE OF SUBMITTING FOR STATE REGISTRATION 405
    • 6.15.3 LICENSING 406
  • 6.16 UKRAINE 406
    • 6.16.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 406
    • 6.16.2 REGULATORY APPROVAL AGENCIES 406
    • 6.16.3 LICENSING AND REGISTRATION 407
    • 6.16.4 POST-MARKETING SURVEILLANCE 408
  • 6.17 BELGIUM 409
    • 6.17.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 409
    • 6.17.2 REGULATORY APPROVAL AGENCIES 409
    • 6.17.3 LICENSING AND REGISTRATION 409
  • 6.18 HUNGARY 409
    • 6.18.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 409
    • 6.18.2 REGULATORY APPROVAL AGENCIES 409
    • 6.18.3 LICENSING AND REGISTRATION 410
    • 6.18.4 POST-MARKETING SURVEILLANCE 410
  • 6.19 LITHUANIA 410
    • 6.19.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 410
    • 6.19.2 REGULATORY APPROVAL AGENCIES 411
  • 6.20 AUSTRIA 411
    • 6.20.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 411
    • 6.20.2 REGULATORY APPROVAL AGENCIES 411
    • 6.20.3 LICENSING AND REGISTRATION 411
    • 6.20.4 POST-MARKETING SURVEILLANCE 411
  • 6.21 IRELAND 412
    • 6.21.1 REGULATORY APPROVAL AGENCIES 412
  • 6.22 NORWAY 413
    • 6.22.1 REGULATORY APPROVAL AGENCIES AND APPROVAL PROCESS 413
  • 6.23 NETHERLANDS 414
    • 6.23.1 REGULATORY APPROVAL AGENCIES AND APPROVAL PROCESS 414
  • 6.24 SWITZERLAND 414
    • 6.24.1 REGULATORY APPROVAL AGENCIES AND APPROVAL PROCESS 414
  • 6.25 JAPAN 415
    • 6.25.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 415
    • 6.25.2 REGULATORY APPROVAL AGENCIES 415
    • 6.25.3 REVIEW, CATEGORIZE, AND PERFORM INGREDIENT ANALYSIS FOR THE AESTHETIC PRODUCT. 415
    • 6.25.4 OBTAINING REQUIRED LICENSES. 416
    • 6.25.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 416
    • 6.25.6 COSMETIC & QUASI-DRUG MARKETING NOTIFICATION SUBMISSION. 416
    • 6.25.7 IMPORT THE COSMETICS AND QUASI DRUGS INTO JAPAN. 416
    • 6.25.8 PRIMARY DISTRIBUTION APPROVAL 416
    • 6.25.9 COSMETIC MANUFACTURING LICENSE (PACKAGING, LABELING, AND STORAGE). 416
  • 6.26 CHINA 417
    • 6.26.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 417
    • 6.26.2 LICENSING AND REGISTRATION 417
    • 6.26.3 REGULATORY APPROVAL AGENCIES 418
    • 6.26.4 POST-MARKETING SURVEILLANCE 418
  • 6.27 SOUTH KOREA 418
    • 6.27.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 418
    • 6.27.2 REGULATORY APPROVAL AGENCIES 419
    • 6.27.3 LICENSING AND REGISTRATION 419
    • 6.27.4 POST-MARKETING SURVEILLANCE 419
    • 6.27.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 419
  • 6.28 INDIA 419
    • 6.28.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 419
    • 6.28.2 LICENSING AND REGISTRATION 420
    • 6.28.3 REGULATORY APPROVAL AGENCIES 421
    • 6.28.4 POST-MARKETING SURVEILLANCE 421
  • 6.29 AUSTRALIA 421
    • 6.29.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 421
    • 6.29.2 REGULATORY APPROVAL AGENCIES 422
    • 6.29.3 LICENSING AND REGISTRATION 422
    • 6.29.4 POST-MARKETING SURVEILLANCE 422
    • 6.29.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 422
  • 6.30 SINGAPORE 422
    • 6.30.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 422
    • 6.30.2 REGULATORY APPROVAL AGENCIES 422
    • 6.30.3 LICENSING AND REGISTRATION 423
    • 6.30.4 POST-MARKETING SURVEILLANCE 423
    • 6.30.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 423
  • 6.31 THAILAND 423
    • 6.31.1 THAILAND DRUG REGISTRATION 423
    • 6.31.2 GENERIC DRUG 423
  • 6.32 MALAYSIA 425
    • 6.32.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 425
    • 6.32.2 REGULATORY APPROVAL AGENCIES 425
    • 6.32.3 LICENSING AND REGISTRATION 425
    • 6.32.4 POST-MARKETING SURVEILLANCE 425
  • 6.33 INDONESIA 426
    • 6.33.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 426
    • 6.33.2 REGULATORY APPROVAL AGENCIES 426
    • 6.33.3 LICENSING AND REGISTRATION 426
  • 6.34 PHILIPPINES 426
    • 6.34.1 GET A LICENSE TO OPERATE FROM THE FDA IN THE PHILIPPINES: 427
  • 6.35 NEW ZEALAND 428
    • 6.35.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 428
    • 6.35.2 TIMELINE 428
    • 6.35.3 REGULATORY APPROVAL AGENCIES 428
    • 6.35.4 LICENSING AND REGISTRATION 429
    • 6.35.5 GOOD CLINICAL PRACTICE REQUIREMENTS 429
  • 6.36 TAIWAN 429
    • 6.36.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 429
    • 6.36.2 TIMELINE: 430
    • 6.36.3 REGULATORY APPROVAL AGENCIES 430
    • 6.36.4 POST MARKETING SURVEILLANCE 430
  • 6.37 CAMBODIA 430
    • 6.37.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 430
    • 6.37.2 REGULATORY APPROVAL AGENCIES 432
    • 6.37.3 LICENSING AND REGISTRATION 432
    • 6.37.4 POST-MARKETING SURVEILLANCE 432
  • 6.38 NEPAL 433
    • 6.38.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 433
    • 6.38.2 REGULATORY APPROVAL AGENCIES 433
  • 6.39 PAKISTAN 433
    • 6.39.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 433
    • 6.39.2 REGULATORY APPROVAL AGENCIES 433
    • 6.39.3 LICENSING AND REGISTRATION 433
  • 6.40 UZBEKISTAN 434
    • 6.40.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 434
    • 6.40.2 REGULATORY APPROVAL AGENCIES 434
    • 6.40.3 LICENSING AND REGISTRATION 434
  • 6.41 VIETNAM 434
    • 6.41.1 REGULATORY APPROVAL TIMELINE 434
    • 6.41.2 REGULATORY APPROVAL AGENCIES 434
    • 6.41.3 LICENSING AND REGISTRATION 434
  • 6.42 BRAZIL 435
    • 6.42.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE: 435
    • 6.42.2 REGULATORY APPROVAL AGENCIES: 436
    • 6.42.3 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 437
  • 6.43 ARGENTINA 437
    • 6.43.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 437
    • 6.43.2 REGULATORY APPROVAL AGENCIES 439
    • 6.43.3 LICENSING AND REGISTRATION 439
  • 6.44 CHILE 440
    • 6.44.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 440
    • 6.44.2 REGULATORY APPROVAL AGENCIES 441
    • 6.44.3 LICENSING AND REGISTRATION 441
  • 6.45 PERU 441
    • 6.45.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 441
  • 6.46 COLOMBIA 442
    • 6.46.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 442
    • 6.46.2 LICENSING AND REGISTRATION 442
    • 6.46.3 REGULATORY APPROVAL AGENCIES 442
  • 6.47 ECUADOR 443
    • 6.47.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 443
    • 6.47.2 REGULATORY APPROVAL AGENCIES 443
    • 6.47.3 LICENSING AND REGISTRATION 443
    • 6.47.4 POST-MARKETING SURVEILLANCE 444
  • 6.48 BOLIVIA 444
    • 6.48.1 REGULATORY AUTHORITY 444
    • 6.48.2 THE REGULATORY FRAMEWORK FOR THE AUTHORIZATION OF DRUGS AND BIOLOGICALS 444
    • 6.48.3 PATHWAYS TO OBTAIN AUTHORIZATION TO DEVELOP, TEST, AND MARKET A PRODUCT 444
    • 6.48.4 MARKETING AUTHORIZATIONS/REGISTRATIONS VALID 444
    • 6.48.5 AUTHORIZATION PROCESS BETWEEN BRAND-NAME PRODUCTS AND GENERIC PRODUCTS 444
  • 6.49 SOUTH AFRICA 445
    • 6.49.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 445
    • 6.49.2 REGULATORY APPROVAL AGENCIES 445
    • 6.49.3 LICENSING AND REGISTRATION 445
    • 6.49.4 POST-MARKETING SURVEILLANCE 446
  • 6.50 SAUDI ARABIA 446
    • 6.50.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 446
    • 6.50.2 REGULATORY APPROVAL AGENCIES 446
    • 6.50.3 LICENSING AND REGISTRATION 447
    • 6.50.4 POST-MARKETING SURVEILLANCE 447
    • 6.50.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 447
  • 6.51 UAE 448
    • 6.51.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 448
    • 6.51.2 LICENSING AND REGISTRATION 449
    • 6.51.3 REGULATORY APPROVAL AGENCIES 450
    • 6.51.4 GOOD MANUFACTURING PRACTICES (GMPS) 450
  • 6.52 EGYPT 450
    • 6.52.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 450
    • 6.52.2 REGULATORY APPROVAL AGENCIES 450
    • 6.52.3 LICENSING AND REGISTRATION 451
    • 6.52.4 POST-MARKETING SURVEILLANCE 451
    • 6.52.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 451
  • 6.53 KUWAIT 451
    • 6.53.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 451
    • 6.53.2 REGULATORY APPROVAL AGENCIES 452
    • 6.53.3 LICENSING AND REGISTRATION 452
  • 6.54 ISRAEL 452
    • 6.54.1 REGULATORY APPROVAL PROCESS 452
    • 6.54.2 TIMELINE 452
    • 6.54.3 REGULATORY APPROVAL AGENCIES 452
    • 6.54.4 LICENSING AND REGISTRATION 452
    • 6.54.5 POST-MARKETING SURVEILLANCE 453
  • 6.55 ALGERIA 454
    • 6.55.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 454
    • 6.55.2 REGULATORY APPROVAL AGENCIES 454
    • 6.55.3 LICENSING AND REGISTRATION 454
  • 6.56 JORDAN 454
    • 6.56.1 REGULATORY APPROVAL AGENCIES, PROCESS, PATHWAYS, AND TIMELINE 454
    • 6.56.2 LICENSING AND REGISTRATION 454
    • 6.56.3 POST-MARKETING SURVEILLANCE 454
  • 6.57 BAHRAIN 455
    • 6.57.1 LICENSING AND REGISTRATION 455
    • 6.57.2 FUNDAMENTAL GUIDELINES FOR TRACEABILITY IN BAHRAIN 456
  • 6.58 IRAQ 456
    • 6.58.1 REGULATORY APPROVAL PROCESS, AGENCIES, FUNCTION 456
  • 6.59 IRAN 457
    • 6.59.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 457
    • 6.59.2 REGULATORY APPROVAL AGENCIES 457
    • 6.59.3 LICENSING AND REGISTRATION 458
  • 6.60 LEBANON 458
    • 6.60.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 458
    • 6.60.2 REGULATORY APPROVAL AGENCIES 458
    • 6.60.3 LICENSING AND REGISTRATION 458
  • 6.61 LIBYA 459
    • 6.61.1 REGULATORY APPROVAL AGENCIES AND FUNCTION 459
  • 6.62 MOROCCO 459
    • 6.62.1 REGULATORY APPROVAL AGENCIES AND FUNCTION 459
  • 6.63 OMAN 459
    • 6.63.1 REGULATORY APPROVAL AGENCIES AND REGISTRATION PROCESS 459
  • 6.64 QATAR 460
    • 6.64.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 460
    • 6.64.2 REGULATORY APPROVAL AGENCIES 460
  • 6.65 TUNISIA 460
    • 6.65.1 REGULATORY APPROVAL AGENCIES AND REGISTRATION PROCESS 460
    • 6.65.2 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES: 462

7 PIPELINE ANALYSIS OF THE GLOBAL FAT REDUCTION MARKET 464

8 MARKET ACCESS 471

  • 8.1 MANUFACTURER AND STRATEGIC DEALS 471
  • 8.2 CURRENT TREATMENT PRACTICES 471
  • 8.3 IMPACT OF UPCOMING THERAPY 472

9 MARKET OVERVIEW 473

  • 9.1 DRIVERS 475
    • 9.1.1 INCREASING DEMAND FOR MINIMALLY INVASIVE AND NON-INVASIVE PROCEDURES 475
    • 9.1.2 GROWING AESTHETIC CONSCIOUSNESS AND BEAUTY STANDARDS 476
    • 9.1.3 GROWING TECHNOLOGICAL ADVANCEMENTS 477
    • 9.1.4 DECREASED DISPARITY BETWEEN MEN AND WOMEN FOR AESTHETIC PROCEDURES 478
  • 9.2 RESTRAINTS 479
    • 9.2.1 HIGH COST OF PROCEDURES 479
    • 9.2.2 INCREASED RISKS ASSOCIATED WITH THE PROCEDURES 480
    • 9.2.3 PRODUCT RECALL 480
  • 9.3 OPPORTUNITIES 481
    • 9.3.1 CUSTOMIZED TREATMENT PLANS AND INTEGRATION WITH OTHER AESTHETIC PROCEDURES 481
    • 9.3.2 BELIEF AND TREND OF FAT REDUCTION IN YOUNG ADULTS 482
    • 9.3.3 FOCUS ON INCLUSIVITY AND DIVERSITY AND EXPANSION OF PRODUCT LINES 484
  • 9.4 CHALLENGES 486
    • 9.4.1 LONG-TERM EFFICACY AND SUSTAINABILITY 486
    • 9.4.2 LONGER RECOVERY TIME OF THE PROCEDURE 486

10 GLOBAL FAT REDUCTION MARKET, BY TYPE 488

  • 10.1 OVERVIEW 489
  • 10.2 SURGICAL FAT REDUCTION 492
    • 10.2.1 LIPOSUCTION 493
      • 10.2.1.1 BY TYPE 494
        • 10.2.1.1.1 ULTRASOUND-ASSISTED LIPOSUCTION 494
        • 10.2.1.1.2 LASER-ASSISTED LIPOSUCTION 495
        • 10.2.1.1.3 TUMESCENT LIPOSUCTION 495
        • 10.2.1.1.4 SUPER-WET TECHNIQUE 495
      • 10.2.1.2 BY APPLICATION 495
        • 10.2.1.2.1 ABDOMINAL FAT 496
        • 10.2.1.2.2 THIGHS FAT 496
        • 10.2.1.2.3 BUTTOCK FAT 496
        • 10.2.1.2.4 UPPER-ARM FAT 496
        • 10.2.1.2.5 FACIAL FAT-DEPOSITS 496
        • 10.2.1.2.5.1 SUBMENTAL AREAS 497
        • 10.2.1.2.5.2 MALAR 497
        • 10.2.1.2.5.3 MANDIBULAR 497
        • 10.2.1.2.6 KNEE FAT 497
    • 10.2.2 SURGICAL REJUVENATION 497
      • 10.2.2.1 FACE LIFT 498
      • 10.2.2.2 NECK LIFT 498
    • 10.2.3 CHIN IMPLANT 498
      • 10.2.3.1 SILICONE CHIN IMPLANTS 499
      • 10.2.3.2 OTHERS 499
    • 10.2.4 PORUS IMPLANTS 499
      • 10.2.4.1 TEFLON 500
      • 10.2.4.2 GORE-TEX 500
      • 10.2.4.3 MEDPORE IMPLANTS 500
  • 10.3 NON-INVASIVE FAT REDUCTION 500
    • 10.3.1 CRYOLIPOLYSIS 503
      • 10.3.1.1 COOL SCULPTING 503
      • 10.3.1.2 COOL SCULPTING ELITE 503
      • 10.3.1.3 COOL TONE 504
      • 10.3.1.4 OTHERS 504
        • 10.3.1.4.1 ABDOMINAL FAT 504
        • 10.3.1.4.2 THIGHS FAT 504
        • 10.3.1.4.3 BUTTOCK FAT 505
        • 10.3.1.4.4 UPPER-ARM FAT 505
        • 10.3.1.4.5 FACIAL FAT-DEPOSITS 505
        • 10.3.1.4.6 KNEE FAT 505
    • 10.3.2 ULTRASOUND 505
      • 10.3.2.1 INTERNAL ULTRASONIC LIPOSUCTION 506
      • 10.3.2.2 EXTERNAL ULTRASONIC LIPOSUCTION 506
        • 10.3.2.2.1 ABDOMINAL FAT 507
        • 10.3.2.2.2 THIGHS FAT 507
        • 10.3.2.2.3 BUTTOCK FAT 507
        • 10.3.2.2.4 UPPER-ARM FAT 507
        • 10.3.2.2.5 FACIAL FAT-DEPOSITS 507
        • 10.3.2.2.6 KNEE FAT 507
    • 10.3.3 RADIOFREQUENCY 508
      • 10.3.3.1 ABDOMINAL FAT 508
      • 10.3.3.2 THIGHS FAT 508
      • 10.3.3.3 BUTTOCK FAT 508
      • 10.3.3.4 UPPER-ARM FAT 508
      • 10.3.3.5 FACIAL FAT-DEPOSITS 509
      • 10.3.3.6 KNEE FAT 509
    • 10.3.4 LOW LEVEL LASER THERAPY 509
      • 10.3.4.1 ABDOMINAL FAT 509
      • 10.3.4.2 THIGHS FAT 509
      • 10.3.4.3 BUTTOCK FAT 510
      • 10.3.4.4 UPPER-ARM FAT 510
      • 10.3.4.5 FACIAL FAT-DEPOSITS 510
      • 10.3.4.6 KNEE FAT 510
    • 10.3.5 OTHERS 510
  • 10.4 MINIMALLY INVASIVE 510
    • 10.4.1 INJECTION LIPOLYSIS 512
      • 10.4.1.1 DEOXYCHOLIC ACID INJECTIONS 512
        • 10.4.1.1.1 KYBELLA/BELKYRA 513
        • 10.4.1.1.1.1 FACIAL FAT-DEPOSITS 514
        • 10.4.1.1.1.2 UPPER-ARM FAT 514
        • 10.4.1.1.1.3 ABDOMINAL FAT 514
        • 10.4.1.1.1.4 THIGHS FAT 514
        • 10.4.1.1.1.5 KNEE FAT 514
        • 10.4.1.1.1.6 BUTTOCK FAT 514
        • 10.4.1.1.2 AQUALYX 515
        • 10.4.1.1.2.1 FACIAL FAT-DEPOSITS 515
        • 10.4.1.1.2.2 UPPER-ARM FAT 515
        • 10.4.1.1.2.3 ABDOMINAL FAT 515
        • 10.4.1.1.2.4 THIGHS FAT 516
        • 10.4.1.1.2.5 KNEE FAT 516
        • 10.4.1.1.2.6 BUTTOCK FAT 516
      • 10.4.1.2 PHOSPHATIDYLCHOLINE 516
        • 10.4.1.2.1 FACIAL FAT-DEPOSITS 517
        • 10.4.1.2.2 UPPER-ARM FAT 517
        • 10.4.1.2.3 ABDOMINAL FAT 517
        • 10.4.1.2.4 THIGHS FAT 517
        • 10.4.1.2.5 KNEE FAT 517
        • 10.4.1.2.6 BUTTOCK FAT 517
      • 10.4.1.3 OTHERS 517
    • 10.4.2 OTHERS 517

11 GLOBAL FAT REDUCTION MARKET, BY APPLICATION 518

  • 11.1 OVERVIEW 519
  • 11.2 ABDOMINAL FAT 522
  • 11.3 THIGHS FAT 523
  • 11.4 BUTTOCK FAT 524
  • 11.5 UPPER-ARM FAT 525
  • 11.6 FACIAL FAT-DEPOSITS 526
    • 11.6.1 SUBMENTAL AREAS 527
    • 11.6.2 MANDIBULAR 527
    • 11.6.3 MALAR 527
  • 11.7 KNEE FAT 527

12 GLOBAL FAT REDUCTION MARKET, BY GENDER 529

  • 12.1 OVERVIEW 530
  • 12.2 FEMALE 533
  • 12.3 MALE 534

13 GLOBAL FAT REDUCTION MARKET, BY AGE GROUP 535

  • 13.1 OVERVIEW 536
  • 13.2 ADULT 539
  • 13.3 GERIATRIC 540
  • 13.4 CHILD 541

14 GLOBAL FAT REDUCTION MARKET, BY END USER 543

  • 14.1 OVERVIEW 544
  • 14.2 HOSPITALS 547
    • 14.2.1 BY TYPE 548
      • 14.2.1.1 PRIVATE 548
      • 14.2.1.2 PUBLIC 548
    • 14.2.2 BY CATEGORY 548
      • 14.2.2.1 TIER 1 549
      • 14.2.2.2 TIER 2 549
      • 14.2.2.3 TIER 3 549
  • 14.3 MULTISPECIALTY CLINICS 549
  • 14.4 DERMATOLOGY CENTERS 550
  • 14.5 MEDICAL SPAS AND BEAUTY CENTERS 551
  • 14.6 OTHERS 552

15 GLOBAL FAT REDUCTION MARKET, BY DISTRIBUTION CHANNEL 554

  • 15.1 OVERVIEW 555
  • 15.2 DIRECT TENDERS 558
  • 15.3 RETAIL SALES 559
  • 15.4 THIRD PARTY DISTRIBUTORS 560
  • 15.5 OTHERS 561

16 GLOBAL FAT REDUCTION MARKET, BY REGION 562

  • 16.1 OVERVIEW 563
  • 16.2 NORTH AMERICA 568
    • 16.2.1 U.S. 588
    • 16.2.2 CANADA 606
    • 16.2.3 MEXICO 623
    • 16.2.4 COSTA RICA 641
    • 16.2.5 DOMINICAN REPUBLIC 659
    • 16.2.6 PANAMA 677
    • 16.2.7 EL SALVADOR 695
    • 16.2.8 GUATEMALA 712
    • 16.2.9 HONDURAS 730
    • 16.2.10 NICARAGUA 747
  • 16.3 EUROPE 764
    • 16.3.1 GERMANY 785
    • 16.3.2 TURKEY 804
    • 16.3.3 ITALY 823
    • 16.3.4 POLAND 842
    • 16.3.5 SPAIN 861
    • 16.3.6 RUSSIA 879
    • 16.3.7 FRANCE 896
    • 16.3.8 NETHERLANDS 914
    • 16.3.9 SWITZERLAND 933
    • 16.3.10 BELGIUM 952
    • 16.3.11 AUSTRIA 970
    • 16.3.12 NORWAY 989
    • 16.3.13 IRELAND 1007
    • 16.3.14 HUNGARY 1025
    • 16.3.15 LITHUANIA 1042
    • 16.3.16 AZERBAIJAN 1060
    • 16.3.17 U.K. 1077
    • 16.3.18 GEORGIA 1093
    • 16.3.19 UKRAINE 1110
    • 16.3.20 REST OF EUROPE 1128
  • 16.4 ASIA PACIFIC 1129
    • 16.4.1 JAPAN 1149
    • 16.4.2 INDIA 1167
    • 16.4.3 CHINA 1184
    • 16.4.4 SOUTH KOREA 1202
    • 16.4.5 THAILAND 1220
    • 16.4.6 MALAYSIA 1237
    • 16.4.7 SINGAPORE 1255
    • 16.4.8 AUSTRALIA 1273
    • 16.4.9 PHILIPPINES 1290
    • 16.4.10 TAIWAN 1308
    • 16.4.11 INDONESIA 1325
    • 16.4.12 NEW ZEALAND 1342
    • 16.4.13 VIETNAM 1359
    • 16.4.14 PAKISTAN 1373
    • 16.4.15 UZBEKISTAN 1390
    • 16.4.16 MYANMAR 1407
    • 16.4.17 NEPAL 1423
    • 16.4.18 CAMBODIA 1439
    • 16.4.19 REST OF ASIA-PACIFIC 1456
  • 16.5 MIDDLE EAST AND AFRICA 1457
    • 16.5.1 SAUDI ARABIA 1476
    • 16.5.2 EGYPT 1492
    • 16.5.3 U.A.E. 1508
    • 16.5.4 SOUTH AFRICA 1525
    • 16.5.5 ISRAEL 1541
    • 16.5.6 KUWAIT 1556
    • 16.5.7 QATAR 1573
    • 16.5.8 OMAN 1589
    • 16.5.9 BAHRAIN 1605
    • 16.5.10 LEBANON 1621
    • 16.5.11 ALGERIA 1638
    • 16.5.12 JORDAN 1655
    • 16.5.13 MOROCCO 1672
    • 16.5.14 IRAN 1689
    • 16.5.15 LIBIYA 1705
    • 16.5.16 IRAQ 1721
    • 16.5.17 TUNISIA 1738
    • 16.5.18 REST OF MIDDLE EAST AND AFRICA 1754
  • 16.6 SOUTH AMERICA 1756
    • 16.6.1 BRAZIL 1774
    • 16.6.2 ARGENTINA 1788
    • 16.6.3 COLOMBIA 1802
    • 16.6.4 CHILE 1816
    • 16.6.5 PERU 1830
    • 16.6.6 EQUADOR 1843
    • 16.6.7 BOLIVIA 1856
    • 16.6.8 PARAGUAY 1869
    • 16.6.9 REST OF SOUTH AMERICA 1882

17 GLOBAL FAT REDUCTION MARKET, COMPANY LANDSCAPE 1883

  • 17.1 COMPANY SHARE ANALYSIS: GLOBAL 1883
  • 17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 1884
  • 17.3 COMPANY SHARE ANALYSIS: EUROPE 1885
  • 17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 1886

18 GLOBAL FAT REDUCTION MARKET, COMPANY LANDSCAPE COUNTRY WISE 1887

  • 18.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 1887
    • 18.1.1 COMPANY SHARE ANALYSIS: U.S. 1887
      • 18.1.1.1 ABBVIE INC. 1888
      • 18.1.1.2 CYNOSURE 1889
      • 18.1.1.3 ALMA LASERS 1890
      • 18.1.1.4 CANDELA CORPORATION 1891
      • 18.1.1.5 MERZ PHARMA 1892
    • 18.1.2 COMPANY SHARE ANALYSIS: CANADA 1893
      • 18.1.2.1 COMPANY SHARE ANALYSIS: CANADA 1893
      • 18.1.2.2 ABBVIE INC. 1894
      • 18.1.2.3 CYNOSURE 1895
      • 18.1.2.4 CANDELA CORPORATION 1896
      • 18.1.2.5 ALMA LASERS 1897

LIST OF FIGURES

  • FIGURE 1 GLOBAL FAT REDUCTION MARKET: SEGMENTATION 235
  • FIGURE 2 GLOBAL FAT REDUCTION MARKET: DATA TRIANGULATION 238
  • FIGURE 3 GLOBAL FAT REDUCTION MARKET: DROC ANALYSIS 239
  • FIGURE 4 GLOBAL FAT REDUCTION MARKET: GLOBAL VS. REGIONAL MARKET ANALYSIS 240
  • FIGURE 5 GLOBAL FAT REDUCTION MARKET: COMPANY RESEARCH ANALYSIS 240
  • FIGURE 6 GLOBAL FAT REDUCTION MARKET: INTERVIEW DEMOGRAPHICS 241
  • FIGURE 7 GLOBAL FAT REDUCTION MARKET: MULTIVARIATE MODELLING 242
  • FIGURE 8 GLOBAL FAT REDUCTION MARKET: DBMR MARKET POSITION GRID 243
  • FIGURE 9 GLOBAL FAT REDUCTION MARKET: VENDOR SHARE ANALYSIS 244
  • FIGURE 10 GLOBAL FAT REDUCTION MARKET: MARKET APPLICATION COVERAGE GRID 245
  • FIGURE 11 GLOBAL FAT REDUCTION MARKET: SEGMENTATION 249
  • FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL FAT REDUCTION MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD FROM 2023 TO 2033 250
  • FIGURE 13 INCREASING DEMAND FOR NON-INVASIVE AND MINIMALLY INVASIVE AESTHETIC PROCEDURES IS EXPECTED TO DRIVE THE GLOBAL FAT REDUCTION MARKET GROWTH IN THE FORECAST PERIOD FROM 2023 TO 2033 251
  • FIGURE 14 THE SURGICAL FAT REDUCTION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL FAT REDUCTION MARKET IN 2023 & 2033 251
  • FIGURE 15 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR THE FAT REDUCTION MANUFACTURERS IN THE FORECAST PERIOD FROM 2023 TO 2033 252
  • FIGURE 16 GMP COMPLIANCE FLOW CHART OF DRUG REVIEW PROCESS FOR CAMBODIA 431
  • FIGURE 17 INSTITUTIONS INVOLVED IN THE APPROVAL PROCESS: 435
  • FIGURE 18 LICENSING AND REGISTRATION: 436
  • FIGURE 19 REGISTRATION PROCESS (STEPS OF REGISTRATION) 436
  • FIGURE 20 PROCEDURE FOR THE REGISTRATION OF PHARMACEUTICAL PRODUCTS (GENERICS) 440
  • FIGURE 21 REGISTRATION PROCESS OF THE MEDICINAL PRODUCTS INTENDED FOR HUMAN USE 461
  • FIGURE 22 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL FAT REDUCTION MARKET 474
  • FIGURE 23 GLOBAL FAT REDUCTION MARKET: BY TYPE, 2022 489
  • FIGURE 24 GLOBAL FAT REDUCTION MARKET: BY TYPE, 2023-2033 (USD MILLION) 490
  • FIGURE 25 GLOBAL FAT REDUCTION MARKET: BY TYPE, CAGR (2023-2033) 490
  • FIGURE 26 GLOBAL FAT REDUCTION MARKET: BY TYPE, LIFELINE CURVE 491
  • FIGURE 27 GLOBAL FAT REDUCTION MARKET: BY APPLICATION, 2022 519
  • FIGURE 28 GLOBAL FAT REDUCTION MARKET: BY APPLICATION, 2023-2033 (USD MILLION) 520
  • FIGURE 29 GLOBAL FAT REDUCTION MARKET: BY APPLICATION, CAGR (2023-2033) 520
  • FIGURE 30 GLOBAL FAT REDUCTION MARKET: BY APPLICATION, LIFELINE CURVE 521
  • FIGURE 31 GLOBAL FAT REDUCTION MARKET: BY GENDER, 2022 530
  • FIGURE 32 GLOBAL FAT REDUCTION MARKET: BY GENDER, 2023-2033 (USD MILLION) 531
  • FIGURE 33 GLOBAL FAT REDUCTION MARKET: BY GENDER, CAGR (2023-2033) 531
  • FIGURE 34 GLOBAL FAT REDUCTION MARKET: BY GENDER, LIFELINE CURVE 532
  • FIGURE 35 GLOBAL FAT REDUCTION MARKET: BY AGE GROUP, 2022 536
  • FIGURE 36 GLOBAL FAT REDUCTION MARKET: BY AGE GROUP, 2023-2033 (USD MILLION) 537
  • FIGURE 37 GLOBAL FAT REDUCTION MARKET: BY AGE GROUP, CAGR (2023-2033) 537
  • FIGURE 38 GLOBAL FAT REDUCTION MARKET: BY AGE GROUP, LIFELINE CURVE 538
  • FIGURE 39 GLOBAL FAT REDUCTION MARKET: BY END USER, 2022 544
  • FIGURE 40 GLOBAL FAT REDUCTION MARKET: BY END USER, 2023-2033 (USD MILLION) 545
  • FIGURE 41 GLOBAL FAT REDUCTION MARKET: BY END USER, CAGR (2023-2033) 545
  • FIGURE 42 GLOBAL FAT REDUCTION MARKET: BY END USER, LIFELINE CURVE 546
  • FIGURE 43 GLOBAL FAT REDUCTION MARKET: BY DISTRIBUTION CHANNEL, 2022 555
  • FIGURE 44 GLOBAL FAT REDUCTION MARKET: BY DISTRIBUTION CHANNEL, 2023-2033 (USD MILLION) 556
  • FIGURE 45 GLOBAL FAT REDUCTION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2033) 556
  • FIGURE 46 GLOBAL FAT REDUCTION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 557
  • FIGURE 47 GLOBAL FAT REDUCTION MARKET: SNAPSHOT (2022) 564
  • FIGURE 48 GLOBAL FAT REDUCTION MARKET: BY REGION (2022) 565
  • FIGURE 49 GLOBAL FAT REDUCTION MARKET: BY REGION (2023 & 2033) 565
  • FIGURE 50 GLOBAL FAT REDUCTION MARKET: BY REGION (2022 & 2033) 566
  • FIGURE 51 GLOBAL FAT REDUCTION MARKET: BY TYPE (2023-2033) 566
  • FIGURE 52 NORTH AMERICA FAT REDUCTION MARKET: SNAPSHOT (2022) 569
  • FIGURE 53 NORTH AMERICA FAT REDUCTION MARKET: BY COUNTRY (2022) 570
  • FIGURE 54 NORTH AMERICA FAT REDUCTION MARKET: BY COUNTRY (2023 & 2033) 570
  • FIGURE 55 NORTH AMERICA FAT REDUCTION MARKET: BY COUNTRY (2022 & 2033) 571
  • FIGURE 56 NORTH AMERICA FAT REDUCTION MARKET: BY TYPE (2023-2033) 571
  • FIGURE 57 EUROPE FAT REDUCTION MARKET: SNAPSHOT (2022) 765
  • FIGURE 58 EUROPE FAT REDUCTION MARKET: BY COUNTRY (2022) 766
  • FIGURE 59 EUROPE FAT REDUCTION MARKET: BY COUNTRY (2023 & 2033) 766
  • FIGURE 60 EUROPE FAT REDUCTION MARKET: BY COUNTRY (2022 & 2033) 767
  • FIGURE 61 EUROPE FAT REDUCTION MARKET: BY TYPE (2023-2033) 767
  • FIGURE 62 ASIA-PACIFIC FAT REDUCTION MARKET: SNAPSHOT (2022) 1130
  • FIGURE 63 ASIA-PACIFIC FAT REDUCTION MARKET: BY COUNTRY (2022) 1131
  • FIGURE 64 ASIA-PACIFIC FAT REDUCTION MARKET: BY COUNTRY (2023 & 2033) 1131
  • FIGURE 65 ASIA-PACIFIC FAT REDUCTION MARKET: BY COUNTRY (2022 & 2033) 1132
  • FIGURE 66 ASIA-PACIFIC FAT REDUCTION MARKET: BY TYPE (2023-2033) 1132
  • FIGURE 67 MIDDLE EAST AND AFRICA FAT REDUCTION MARKET: SNAPSHOT (2022) 1458
  • FIGURE 68 MIDDLE EAST AND AFRICA FAT REDUCTION MARKET: BY COUNTRY (2022) 1459
  • FIGURE 69 MIDDLE EAST AND AFRICA FAT REDUCTION MARKET: BY COUNTRY (2023 & 2033) 1459
  • FIGURE 70 MIDDLE EAST AND AFRICA FAT REDUCTION MARKET: BY COUNTRY (2022 & 2033) 1460
  • FIGURE 71 MIDDLE EAST AND AFRICA FAT REDUCTION MARKET: BY TYPE (2023-2033) 1460
  • FIGURE 72 SOUTH AMERICA FAT REDUCTION MARKET: SNAPSHOT (2022) 1757
  • FIGURE 73 SOUTH AMERICA FAT REDUCTION MARKET: BY COUNTRY (2022) 1758
  • FIGURE 74 SOUTH AMERICA FAT REDUCTION MARKET: BY COUNTRY (2023 & 2033) 1758
  • FIGURE 75 SOUTH AMERICA FAT REDUCTION MARKET: BY COUNTRY (2022 & 2033) 1759
  • FIGURE 76 SOUTH AMERICA FAT REDUCTION MARKET: BY TYPE (2023-2033) 1759
  • FIGURE 77 GLOBAL FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1883
  • FIGURE 78 NORTH AMERICA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1884
  • FIGURE 79 EUROPE FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1885
  • FIGURE 80 ASIA-PACIFIC FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1886
  • FIGURE 81 THE U.S. FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1887
  • FIGURE 82 ABBVIE INC.IN U.S. FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1888
  • FIGURE 83 CYNOSURE IN U.S. FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1889
  • FIGURE 84 ALMA LASERS IN U.S. FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1890
  • FIGURE 85 CANDELA CORPORATION IN U.S. FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1891
  • FIGURE 86 MERZ PHARMA IN U.S. FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1892
  • FIGURE 87 THE CANADA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1893
  • FIGURE 88 ABBVIE INC.IN CANADA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1894
  • FIGURE 89 CYNOSURE IN CANADA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1895
  • FIGURE 90 CANDELA CORPORATION IN CANADA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1896
  • FIGURE 91 ALMA LASERS IN CANADA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1897
  • FIGURE 92 MERZ PHARMA IN CANADA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1898
  • FIGURE 93 THE MEXICO FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1899
  • FIGURE 94 ABBVIE INC.IN MEXICO FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1900
  • FIGURE 95 ALMA LASERS IN MEXICO FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1901
  • FIGURE 96 CANDELA CORPORATION IN MEXICO FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1902
  • FIGURE 97 MERZ PHARMA IN CANADA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1903
  • FIGURE 98 THE COSTA RICA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1904
  • FIGURE 99 ALMA LASERS IN DOMINICAN REPUBLIC FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1905
  • FIGURE 100 CANDELA CORPORATION IN COSTA RICA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1906
  • FIGURE 101 DEXLEVO AESTHETICS IN GUATEMALA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1907
  • FIGURE 102 THE DOMINICAN REPUBLIC FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1908
  • FIGURE 103 ABBVIE INC IN DOMINICAN REPUBLIC FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1909
  • FIGURE 104 ALMA LASERS IN DOMINICAN REPUBLIC FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1910
  • FIGURE 105 THE GUATEMALA S FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1911
  • FIGURE 106 ALMA LASERS IN GUATEMALA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1912
  • FIGURE 107 CANDELA CORPORATION IN GUATEMALA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1913
  • FIGURE 108 THE HONDURUS FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1914
  • FIGURE 109 ALMA LASERS IN HONDURUS FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1915
  • FIGURE 110 CANDELA CORPORATION IN HONDURUS FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1916
  • FIGURE 111 THE PANAMA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1917
  • FIGURE 112 ALMA LASERS IN PANAMA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1918
  • FIGURE 113 CANDELA CORPORATION IN PANAMA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1919
  • FIGURE 114 THE EL SALVADOR FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1920
  • FIGURE 115 ALMA LASERS IN EL SALVADOR FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1921
  • FIGURE 116 THE NICARAGUA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1922
  • FIGURE 117 ALMA LASERS IN NICARAGUA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1923
  • FIGURE 118 THE GERMANY FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1924
  • FIGURE 119 ABBVIE INC.IN GERMANY FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1925
  • FIGURE 120 CYNOSURE IN GERMANY FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1926
  • FIGURE 121 ALMA LASERS IN GERMANY FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1927
  • FIGURE 122 CANDELA CORPORATION IN GERMANY FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1928
  • FIGURE 123 MERZ PHARMA IN U.S. FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1929
  • FIGURE 124 THE FRANCE FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1930
  • FIGURE 125 ABBVIE INC.IN FRANCE FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1931
  • FIGURE 126 CYNOSURE IN FRANCE FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1932
  • FIGURE 127 CANDELA CORPORATION IN FRANCE FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1933
  • FIGURE 128 VENOUS CONCEPT IN FRANCE FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1934
  • FIGURE 129 THE U.K. FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1935
  • FIGURE 130 ABBVIE INC.IN U.K. FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1936
  • FIGURE 131 CYNOSURE IN U.K. IN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1937
  • FIGURE 132 ALMA LASERS IN U.K FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1938
  • FIGURE 133 CANDELA CORPORATION IN U.K. IN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1939
  • FIGURE 134 MERZ PHARMA IN U.S. FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1940
  • FIGURE 135 THE ITALY FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1941
  • FIGURE 136 ABBVIE INC.IN ITALY FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1942
  • FIGURE 137 CANDELA CORPORATION IN ITALY IN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1943
  • FIGURE 138 MERZ PHARMA IN ITALY IN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1944
  • FIGURE 139 MENTOR WORLDWIDE LLC IN BRAZIL FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1945
  • FIGURE 140 THE SPAIN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1946
  • FIGURE 141 ABBVIE INC.IN SPAIN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1947
  • FIGURE 142 CYNOSURE IN SPAIN IN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1948
  • FIGURE 143 CANDELA CORPORATION IN SPAIN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1949
  • FIGURE 144 THE RUSSIA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1950
  • FIGURE 145 ABBVIE INC.IN RUSSIA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1951
  • FIGURE 146 CANDELA CORPORATION IN RUSSIA FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1952
  • FIGURE 147 MERZ PHARMA IN RUSSIA IN FAT REDUCTION MARKET: COMPANY SHARE 2022 (%) 1953